---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-26-000010"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:51:14.054220+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pelthos Therapeutics acquires Xeglyze (abametapir) head lice treatment for $1.8M

## Summary
- Total purchase price $1.8M; $450K deposit paid Nov 20, 2025, $1.35M paid at closing Dec 23, 2025.
- Xeglyze is FDA-approved (Jul 2020) for head lice in patients 6 months+; single 10-minute application.
- No future milestone, royalty, or other payments owed to Hatchtech; worldwide commercialization rights.
- Pelthos plans to relaunch Xeglyze in first half of 2027.
- CEO Scott Plesha says acquisition aligns with strategy of commercializing innovative products.

## SEC filing metadata
- accession: 0001753926-26-000010
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392626000010/0001753926-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392626000010/g085066_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-26-000010
- JSON: https://secwatch.observer/filing/0001753926-26-000010.json
- Plain text: https://secwatch.observer/filing/0001753926-26-000010.txt

## Source-grounded claims
- claim_id: 572e2c111a588d904ee417cb182bcc6598554f18
  claim: Pelthos Therapeutics Inc. entered into Asset Purchase Agreement with Hatchtech Pty Ltd valued at $1,800,000 aggregate purchase price (including $450,000 down payment paid on November 20, 2025 and $ (effective 2025-12-23).
  evidence_excerpt: On December 23, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”) entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Hatchtech Pty Ltd ACN 098 559 409, an Australian corporation (“ Hatchtech ”), pursuant to which Hatchtech sold all of its right, title and interest in (i) the product developed by Hatchtech with Abametapir as its sole active ingredient for the treatment of head lice infestation in humans (the “ Xeglyze Product ”), (ii) all intangible assets of Hatchtech including intellectual property of Hatchtech relating to the Xeglyze Product, including, without limitation (A) certain patent and patent applications, together with all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, and renewals and (B) certain trademarks, service marks, trade names and registered user names, including registrations and applications for registration thereof, together with all goodwill associated therewi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1919246/000175392626000010/0001753926-26-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.